Ei­sai, BioArc­tic to de­vel­op new drug for Alzheimer’s that can cross blood-brain bar­ri­er

Ei­sai and BioArc­tic — the com­pa­nies be­hind the first Alzheimer’s drug proven to slow dis­ease pro­gres­sion — are ink­ing an­oth­er re­search part­ner­ship in the dis­ease, this time uti­liz­ing the Swedish biotech’s new brain de­liv­ery tech­nol­o­gy.

The com­pa­nies will share the costs of the re­search eval­u­a­tion project for BioArc­tic’s pre­clin­i­cal Alzheimer’s pro­gram BAN2802. The as­set com­bines the biotech’s Brain­Trans­porter tech­nol­o­gy with an Alzheimer’s drug can­di­date with an undis­closed tar­get, per a Sat­ur­day re­lease. At the end of the col­lab­o­ra­tion, Ei­sai will eval­u­ate the da­ta gen­er­at­ed and de­cide whether to ex­er­cise its op­tion for BAN2802.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER